SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Pla
Journey Medical Corp (NASDAQ:DERM) has reported an insider purchase according to the latest SEC filings.
Journey Medical ( NASDAQ:DERM ) Full Year 2023 Results Key Financial Results Revenue: US$79.2m (up 7.5% from FY 2022...